Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia (BFORE trial): 24-month efficacy update and results by 3-month BCR-ABL1 transcript levels Meeting Abstract
| Authors: | Brümmendorf, T. H.; Hochhaus, A.; Isfort, S.; le Coutre, P.; Jentsch-Ullrich, K.; Schafhausen, P.; Gambacorti-Passerini, C.; Deininger, M. W.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Kota, V.; Lipton, J. H.; Crescenzo, R. J.; Leip, E.; Viqueira, A.; Bardy-Bouxin, N.; Cortes, J. E. |
| Abstract Title: | Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia (BFORE trial): 24-month efficacy update and results by 3-month BCR-ABL1 transcript levels |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 41 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2018 Sep 28-Oct 2 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2018-09-01 |
| Start Page: | 138 |
| Language: | English |
| ACCESSION: | WOS:000446816500333 |
| PROVIDER: | wos |
| PUBMED: | 30261496 |
| DOI: | 10.1159/000492737 |
| Notes: | Meeting Abstract: V414 -- Source: Wos |
